Taher Darreh-Shori

Summary

Affiliation: Karolinska Institutet
Country: Sweden

Publications

  1. doi request reprint Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease
    Taher Darreh-Shori
    Division of Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Neurobiol Aging 34:2465-81. 2013
  2. doi request reprint Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease
    Taher Darreh-Shori
    Division of Alzheimer Neurobiology Center, Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden
    J Alzheimers Dis 28:443-58. 2012
  3. doi request reprint The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase
    Taher Darreh-Shori
    Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Sweden
    Neurobiol Aging 32:1236-48. 2011
  4. doi request reprint Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia
    Taher Darreh-Shori
    Karolinska University Hospital, Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Novum, 4th Floor, Room 4F23 10, 141 86, Huddinge, Stockholm, Sweden
    Expert Opin Drug Saf 9:167-76. 2010
  5. doi request reprint Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo
    Taher Darreh-Shori
    Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska Institutet, Stockholm, Sweden
    Neurobiol Aging 32:2320.e15-32. 2011
  6. pmc Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease
    Ahmadul Kadir
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Brain 134:301-17. 2011
  7. ncbi request reprint Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET
    Ahmadul Kadir
    Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Division of Molecular Neuropharmacology, Karolinska University Hospital Huddinge, Novum floor 5, 141 86, Stockholm, Sweden
    Psychopharmacology (Berl) 191:1005-14. 2007
  8. pmc Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients
    Agneta Nordberg
    Karolinska Institute, Division of Alzheimer Neurobiology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Curr Alzheimer Res 6:4-14. 2009
  9. doi request reprint Unbiased expression mapping identifies a link between the complement and cholinergic systems in the rat central nervous system
    Rickard P F Lindblom
    Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden
    J Immunol 192:1138-53. 2014
  10. doi request reprint Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors
    Taher Darreh-Shori
    Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska Institute, Stockholm, Sweden
    J Alzheimers Dis 39:423-40. 2014

Collaborators

Detail Information

Publications12

  1. doi request reprint Functional variability in butyrylcholinesterase activity regulates intrathecal cytokine and astroglial biomarker profiles in patients with Alzheimer's disease
    Taher Darreh-Shori
    Division of Alzheimer Neurobiology Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
    Neurobiol Aging 34:2465-81. 2013
    ..Further studies are needed to explore the therapeutic potential of manipulating BuChE activity or astroglial functional status...
  2. doi request reprint Apolipoprotein ε4 modulates phenotype of butyrylcholinesterase in CSF of patients with Alzheimer's disease
    Taher Darreh-Shori
    Division of Alzheimer Neurobiology Center, Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Stockholm, Sweden
    J Alzheimers Dis 28:443-58. 2012
    ..APOE4-dependent outcome of BCHE-K genotype as AD risk factor arises through a differential phenotypic modulation of BuChE. Future pharmacogenetic studies should include assessment of the subjects' true phenotypic display of BuChE...
  3. doi request reprint The apolipoprotein E ε4 allele plays pathological roles in AD through high protein expression and interaction with butyrylcholinesterase
    Taher Darreh-Shori
    Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Sweden
    Neurobiol Aging 32:1236-48. 2011
    ..In conclusion, ApoE ε4 might impart its pathological role through high protein expression and interaction with BuChE, which in turn might modulate central cholinergic activity and Aβ load in the brain...
  4. doi request reprint Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia
    Taher Darreh-Shori
    Karolinska University Hospital, Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Novum, 4th Floor, Room 4F23 10, 141 86, Huddinge, Stockholm, Sweden
    Expert Opin Drug Saf 9:167-76. 2010
    ..It is also approved for the treatment of Parkinson's disease dementia (PDD) in many countries. The objective of this article is to review the safety and tolerability profile of transdermal and oral rivastigmine in AD and PDD patients...
  5. doi request reprint Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo
    Taher Darreh-Shori
    Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska Institutet, Stockholm, Sweden
    Neurobiol Aging 32:2320.e15-32. 2011
    ....
  6. pmc Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease
    Ahmadul Kadir
    Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Brain 134:301-17. 2011
    ....
  7. ncbi request reprint Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET
    Ahmadul Kadir
    Karolinska Institute, Department of Neurobiology, Care Sciences and Society, Division of Molecular Neuropharmacology, Karolinska University Hospital Huddinge, Novum floor 5, 141 86, Stockholm, Sweden
    Psychopharmacology (Berl) 191:1005-14. 2007
    ..Thus, we used positron emission tomography (PET) technique as a sensitive approach to assess longitudinal changes in the nicotine binding sites in the brains of patients with AD...
  8. pmc Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients
    Agneta Nordberg
    Karolinska Institute, Division of Alzheimer Neurobiology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Curr Alzheimer Res 6:4-14. 2009
    ....
  9. doi request reprint Unbiased expression mapping identifies a link between the complement and cholinergic systems in the rat central nervous system
    Rickard P F Lindblom
    Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden
    J Immunol 192:1138-53. 2014
    ....
  10. doi request reprint Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors
    Taher Darreh-Shori
    Department of Neurobiology, Care Sciences and Society, Division of Alzheimer Neurobiology, Karolinska Institute, Stockholm, Sweden
    J Alzheimers Dis 39:423-40. 2014
    ....
  11. ncbi request reprint Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies
    T Darreh-Shori
    Karolinska Institutet, Division of Alzheimer Neurobiology, Karolinska University Hospital Huddinge
    Curr Alzheimer Res 7:67-73. 2010
    ..These findings suggest that these agents exert different effects on CSF cholinesterases. The clinical effects of these pharmacological differences are yet to be fully established...